Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5695191 | 0.98 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5695254 | 0.90 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5695242 | 0.90 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL5695255 | 0.88 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL5695308 | 0.88 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5695217 | 0.86 | ALDH1A1 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL6499649 | 0.85 | ALDH1A1 (0.45) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5695258 | 0.83 | GAA (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL28050241 | 0.82 | RAB9A (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1973833 | 0.82 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-09 | — | — | US | claimed |
| EP-1341770-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | claimed |
| WO-2002046169-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | claimed |
| CN-112341431-A | Heterocyclic compounds as FGFR4 inhibitors | 齐鲁制药有限公司 | 2021-02-09 | — | — | CN | disclosed |
| US-8067614-B2 | N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168196-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20080167359-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1592671-B1 | N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1341770-B1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1592671-A1 | N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-6958357-B2 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-25 | — | — | US | disclosed |
| US-20050054705-A1 | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004069811-A1 | N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
| US-6686384-B2 | 2-ANILINOPHENYL-SUBSTITUTED; INHIBITION OF THE NA+/H+ EXCHANGER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-09 | — | — | US | disclosed |
| EP-1341770-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002046169-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167359-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SLC10A1, SLC9A3, ABCB11 | NPC1 12/4885RAB9A 2051/4885SMN1; SMN2 674/4885 |
| US-20100168196-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SLC10A1, SLC9A3, ABCB11 | NPC1 12/4885RAB9A 2051/4885SMN1; SMN2 674/4885 |
| US-20050054705-A1 | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | SLC10A1, SLC9A3, NHERF1 | NPC1 17/4885RAB9A 1936/4885SMN1; SMN2 651/4885 |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | NPC1 220/4885RAB9A 914/4885SMN1; SMN2 3413/4885 |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | NPC1 220/4885RAB9A 914/4885SMN1; SMN2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.